Testosterone Levels Are Decreased and Associated with Disease Duration in Male Spinocerebellar Ataxia Type 2 Patients.

Autor: Almaguer-Mederos, Luis E., Aguilera-Rodríguez, Raúl, Almaguer-Gotay, Dennis, Hechavarría-Barzaga, Kenia, Álvarez-Sosa, Amarilis, Chapman-Rodríguez, Yamilé, Silva-Ricardo, Yanelis, González-Zaldivar, Yanetza, Vázquez-Mojena, Yaimé, Cuello-Almarales, Dany, Rodríguez-Estupiñán, Annelié
Předmět:
Zdroj: Cerebellum; Aug2020, Vol. 19 Issue 4, p597-604, 8p
Abstrakt: Spinocerebellar ataxia type 2 (SCA2) is a progressive neurodegenerative disorder due to an unstable expansion of a CAG repeat in the ATXN2 gene. Despite clinical and experimental evidence indicating the relevance of the gonadotropic axis to the prognosis and therapeutics for several late-onset neurodegenerative disorders, its functioning and association with disease severity have not been previously explored in SCA2. To assess serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), and their clinical relevance in SCA2 patients. A case-control study involving 94 Cuban SCA2 patients and 101 gender- and age-matched healthy controls was conducted. Testosterone, LH, and FSH serum levels were determined by radioimmunoassay or immunoradiometric assay systems. Clinical outcomes included age at onset, disease duration, Scale for the Assessment and Rating of Ataxia (SARA) score, and progression rate. Univariate general linear models were generated. Testosterone, LH, and FSH serum levels were significantly reduced in male SCA2 patients relative to control individuals. On average, there was a 35% reduction in testosterone levels in male patients versus male control individuals. Testosterone levels were associated with disease duration (r = 0.383; p = 0.025) and age at onset (r = 0.414; p = 0.011) in male SCA2 patients, but no association was observed between testosterone and CAG expansion size, SARA score, or progression rate. Testosterone levels might be a biomarker of disease progression in male SCA2 patients. Further studies are needed to explore the effects of low testosterone levels on non-motor symptoms, and to assess the potential of testosterone replacement therapy in male SCA2 patients. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: